[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551713":3},{"organization":4,"armGroups":7,"interventions":32,"overallOfficials":61,"centralContacts":61,"locations":62,"responsibleParty":318,"collaborators":320,"id":323,"slug":324,"hasResults":325,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":325,"sex":331,"minAge":332,"maxAge":61,"enrollmentInfo":333,"targetDuration":61,"studyType":336,"phases":337,"briefSummary":339,"conditions":340,"keywords":349,"overallStatus":65,"whyStopped":61,"lastUpdateSubmitDate":385,"lastUpdatePostDateStruct":386,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":394},{"fullName":5,"class":6},"Genelux Corporation","INDUSTRY",[8,17,21,27],{"label":9,"type":10,"description":11,"interventionNames":12},"Single-arm run-in Olvi-Vec dose escalation Cohorts","EXPERIMENTAL","Cohort 1: Olvi-Vec administered over 3 consecutive days at 0.5,0.5,0.5 x 10e9 pfu followed 2 to 3 weeks later with platinum-doublet chemotherapy + Physician's Choice of ICI.\n\nCohort 2: Olvi-Vec administered over 3 consecutive days at 1,1,1 x 10e9 pfu followed 2 to 3 weeks later with platinum-doublet chemotherapy + Physician's Choice of ICI.\n\nCohort 3: Olvi-Vec administered over 4 consecutive days at 1,2,3 x 10e9 pfu followed 2 to 3 weeks later with platinum-doublet chemotherapy + Physician's Choice of ICI.",[13,14,15,16],"Biological: Olvimulogene nanivacirepvec","Drug: Platinum chemotherapy: carboplatin or cisplatin","Drug: Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC","Drug: Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab",{"label":18,"type":10,"description":19,"interventionNames":20},"Experimental Arm","Olvi-Vec will be administered at the dose and schedule selected from the single-arm run-in Olvi-Vec dose escalation cohorts followed 2 to 3 weeks later with platinum-doublet chemotherapy + Physician's Choice of ICI.",[13,14,15,16],{"label":22,"type":23,"description":24,"interventionNames":25},"Active Comparator Arm","ACTIVE_COMPARATOR","Docetaxel starts in Week 0 and continues until disease progression is assessed by the BICR.",[26],"Drug: Docetaxel",{"label":28,"type":29,"description":30,"interventionNames":31},"Active Comparator Arm Cross-over","OTHER","Patients randomized into the Active Comparator can cross-over to receive the same treatment as given in the Experimental Arm following determination of (1) disease progression by BICR after receiving docetaxel treatment and (2) confirming eligibility.",[13,14,15,16,26],[33,42,49,53,57],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"BIOLOGICAL","Olvimulogene nanivacirepvec","Olvi-Vec is an engineered oncolytic vaccinia virus",[28,18,9],[39,40,41],"Olvi-Vec","GL-ONC","GLV-1h68",{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"DRUG","Platinum chemotherapy: carboplatin or cisplatin","Administered according to local practice.",[28,18,9],[48],"Brand of drug is based on institutional procurement",{"type":43,"name":50,"description":45,"armGroupLabels":51,"otherNames":52},"Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC",[28,18,9],[48],{"type":43,"name":54,"description":45,"armGroupLabels":55,"otherNames":56},"Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab",[28,18,9],[48],{"type":43,"name":58,"description":45,"armGroupLabels":59,"otherNames":60},"Docetaxel",[22,28],[48],null,[63,85,102,117,133,152,167,181,194,210,227,243,260,282,299],{"facility":64,"status":65,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":76,"contacts":77},"Pioneer Research Center, LLC","RECRUITING","Bullhead City","Arizona","86442","United States","US",{"type":72,"coordinates":73},"Point",[74,75],-114.5683,35.14778,{"lat":75,"lon":74},[78,83],{"name":79,"role":80,"phone":81,"phoneExt":61,"email":82},"Hamdy Mohtaseb, MD","CONTACT","928-216-4560","hmohtaseb@azcancerandblood.com",{"name":79,"role":84,"phone":61,"phoneExt":61,"email":61},"PRINCIPAL_INVESTIGATOR",{"facility":86,"status":65,"city":87,"state":88,"zip":89,"country":69,"countryCode":70,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Clermont Oncology Center","Clermont","Florida","34711",{"type":72,"coordinates":91},[92,93],-81.77285,28.54944,{"lat":93,"lon":92},[96,100],{"name":97,"role":80,"phone":98,"phoneExt":61,"email":99},"Kiran Penta","386-538-3169","kiran@aorcorp.com",{"name":101,"role":84,"phone":61,"phoneExt":61,"email":61},"Gopal Kunta, MD",{"facility":103,"status":65,"city":104,"state":88,"zip":105,"country":69,"countryCode":70,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Oncology & Hematology Associates of West Broward","Coral Springs","33065",{"type":72,"coordinates":107},[108,109],-80.2706,26.27119,{"lat":109,"lon":108},[112,116],{"name":113,"role":80,"phone":114,"phoneExt":61,"email":115},"Sumit Sawhney, MD","954-726-0035","sumit@bellsouth.net",{"name":113,"role":84,"phone":61,"phoneExt":61,"email":61},{"facility":118,"status":65,"city":119,"state":88,"zip":120,"country":69,"countryCode":70,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Helios Clinical Research","Fort Lauderdale","33316",{"type":72,"coordinates":122},[123,124],-80.14338,26.12231,{"lat":124,"lon":123},[127,131],{"name":128,"role":80,"phone":129,"phoneExt":61,"email":130},"Kylee Charlemagne","645-225-9003","kylee.charlemagne@heliosclinical.com",{"name":132,"role":84,"phone":61,"phoneExt":61,"email":61},"Edgardo Santos, MD",{"facility":134,"status":65,"city":135,"state":88,"zip":136,"country":69,"countryCode":70,"cosmosGeoPoint":137,"geoPoint":141,"contacts":142},"Bioresearch Partner","Hialeah","33013",{"type":72,"coordinates":138},[139,140],-80.27811,25.8576,{"lat":140,"lon":139},[143,147,150],{"name":144,"role":80,"phone":145,"phoneExt":61,"email":146},"Jenrrys Mejias","833-489-4968","jmejias@bioresearchpartner.com",{"name":148,"role":80,"phone":145,"phoneExt":61,"email":149},"Jonathan Matias","jmatias@bioresearchpartner.com",{"name":151,"role":84,"phone":61,"phoneExt":61,"email":61},"Luis Rangel, MD",{"facility":153,"status":65,"city":154,"state":88,"zip":155,"country":69,"countryCode":70,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"University of Miami - Sylvester Comprehensive Cancer Center","Miami","33136",{"type":72,"coordinates":157},[158,159],-80.19366,25.77427,{"lat":159,"lon":158},[162,166],{"name":163,"role":80,"phone":164,"phoneExt":61,"email":165},"Richa Dawar, MD","954-461-2107","richa.dawar@med.miami.edu",{"name":163,"role":84,"phone":61,"phoneExt":61,"email":61},{"facility":134,"status":65,"city":154,"state":88,"zip":168,"country":69,"countryCode":70,"cosmosGeoPoint":169,"geoPoint":171,"contacts":172},"33155",{"type":72,"coordinates":170},[158,159],{"lat":159,"lon":158},[173,176,179],{"name":174,"role":80,"phone":145,"phoneExt":61,"email":175},"Handy Del Sol Bello","handy@bioresearchpartner.com",{"name":177,"role":80,"phone":145,"phoneExt":61,"email":178},"Marianna Wefer","mwefer@bioresearchpartner.com",{"name":180,"role":84,"phone":61,"phoneExt":61,"email":61},"Javier Perez Fernandez, MD",{"facility":182,"status":65,"city":183,"state":88,"zip":184,"country":69,"countryCode":70,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Mid Florida Hematology and Oncology Center","Orange City","32763",{"type":72,"coordinates":186},[187,188],-81.29867,28.94888,{"lat":188,"lon":187},[191,192],{"name":97,"role":80,"phone":98,"phoneExt":61,"email":99},{"name":193,"role":84,"phone":61,"phoneExt":61,"email":61},"Santosh Nair, MD",{"facility":195,"status":65,"city":196,"state":88,"zip":197,"country":69,"countryCode":70,"cosmosGeoPoint":198,"geoPoint":202,"contacts":203},"BRCR Medical Center, Inc.","Plantation","33322",{"type":72,"coordinates":199},[200,201],-80.23184,26.13421,{"lat":201,"lon":200},[204,208],{"name":205,"role":80,"phone":206,"phoneExt":61,"email":207},"Anamaria Astudillo","561-447-0614","anamariaa@brcrglobal.com",{"name":209,"role":84,"phone":61,"phoneExt":61,"email":61},"Harshad Amin, MD",{"facility":211,"status":65,"city":212,"state":213,"zip":214,"country":69,"countryCode":70,"cosmosGeoPoint":215,"geoPoint":219,"contacts":220},"Michigan Hematology and Oncology Consultants","Dearborn","Michigan","48126",{"type":72,"coordinates":216},[217,218],-83.17631,42.32226,{"lat":218,"lon":217},[221,225],{"name":222,"role":80,"phone":223,"phoneExt":61,"email":224},"Heather Austin","585-216-7617","heather.austin@profoundresearch.com",{"name":226,"role":84,"phone":61,"phoneExt":61,"email":61},"Faisel Musa, MD",{"facility":228,"status":65,"city":229,"state":213,"zip":230,"country":69,"countryCode":70,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"Oakland Medical Group","Farmington Hills","48336",{"type":72,"coordinates":232},[233,234],-83.37716,42.48531,{"lat":234,"lon":233},[237,241],{"name":238,"role":80,"phone":239,"phoneExt":61,"email":240},"Catherine Maples","517-375-3057","Catherine.Maples@profoundresearch.com",{"name":242,"role":84,"phone":61,"phoneExt":61,"email":61},"Jeffrey Margolis, MD",{"facility":244,"status":65,"city":245,"state":246,"zip":247,"country":69,"countryCode":70,"cosmosGeoPoint":248,"geoPoint":252,"contacts":253},"Inspira Medical Center Mullica Hill","Mullica Hill","New Jersey","08062",{"type":72,"coordinates":249},[250,251],-75.22407,39.73928,{"lat":251,"lon":250},[254,258],{"name":255,"role":80,"phone":256,"phoneExt":61,"email":257},"Research","856-641-6989","research@ihn.org",{"name":259,"role":84,"phone":61,"phoneExt":61,"email":61},"Erev Tubb, MD",{"facility":261,"status":65,"city":262,"state":263,"zip":264,"country":69,"countryCode":70,"cosmosGeoPoint":265,"geoPoint":269,"contacts":270},"Gabrail Cancer and Research Center","Canton","Ohio","44718",{"type":72,"coordinates":266},[267,268],-81.37845,40.79895,{"lat":268,"lon":267},[271,276,280],{"name":272,"role":80,"phone":273,"phoneExt":274,"email":275},"Carrie Smith","330-492-3345","208","csmith@gabrailcancercenter.com",{"name":277,"role":80,"phone":273,"phoneExt":278,"email":279},"Kim Roby","227","kroby@gabrailcancercenter.com",{"name":281,"role":84,"phone":61,"phoneExt":61,"email":61},"Nashat Gabrail, MD",{"facility":283,"status":65,"city":284,"state":285,"zip":286,"country":69,"countryCode":70,"cosmosGeoPoint":287,"geoPoint":291,"contacts":292},"Texas Oncology - Austin Central","Austin","Texas","78745",{"type":72,"coordinates":288},[289,290],-97.74306,30.26715,{"lat":290,"lon":289},[293,297],{"name":294,"role":80,"phone":295,"phoneExt":61,"email":296},"Marian Heaven, BSN","512-427-9400","Marian.heaven@usoncology.com",{"name":298,"role":84,"phone":61,"phoneExt":61,"email":61},"James Uyeki, MD",{"facility":300,"status":65,"city":301,"state":285,"zip":302,"country":69,"countryCode":70,"cosmosGeoPoint":303,"geoPoint":307,"contacts":308},"World Research Link","Baytown","77521",{"type":72,"coordinates":304},[305,306],-94.97743,29.7355,{"lat":306,"lon":305},[309,313,316],{"name":310,"role":80,"phone":311,"phoneExt":61,"email":312},"Isabel Navarrete","833-832-8328","isabel.navarrete@worldresearchlink.com",{"name":314,"role":80,"phone":311,"phoneExt":61,"email":315},"Dustyn Tobin, MD","dr.tobin@worldresearchlink.com",{"name":317,"role":84,"phone":61,"phoneExt":61,"email":61},"Amir Rasheed, MD",{"type":319,"investigatorFullName":61,"investigatorTitle":61,"investigatorAffiliation":61,"oldNameTitle":61,"oldOrganization":61},"SPONSOR",[321],{"name":322,"class":6},"Newsoara Biopharma Co., Ltd.","100551713","phase-2-efficacy--safety-of-olvimulogene-nanivacirepvec--platinum-doublet--physicians-choice-of-immune-checkpoint-inhibitor-compared-to-docetaxel-in-nscl-cancer-100551713",false,"NCT06463665","Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance","VIRO-25","Inclusion Criteria:\n\n* Male or female 18 years or older.\n* ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1.\n* Have histologically or cytologically confirmed advanced or metastatic NSCLC.\n* Histologically confirmed Stage III or IV squamous or nonsquamous \\[American Joint Committee on Cancer (AJCC) 8th edition\\].\n* Received at least 2 cycles and maximum of 6 cycles of front-line platinum-based chemotherapy with ICI-based therapy, regardless of PD-L1 expression.\n* Reached first disease progression by radiological assessment while receiving front-line or maintenance ICI.\n* At least one measurable target tumor lesion anywhere except the brain per RECIST 1.1 by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan.\n* Have adequate renal, hepatic, bone marrow function as well as adequate coagulation tests \\[International Normalized Ratio (INR)\\] and adequate immune function by lymphocyte count.\n* Women of child-bearing potential must have a negative serum pregnancy test prior to initiating study dosing.\n* Be willing and able to comply with scheduled visits, the treatment plan, imaging and laboratory tests.\n\nExclusion Criteria:\n\n* Active and untreated urinary tract infection, pneumonia, or other systemic infections.\n* Current symptomatic central nervous system (CNS) metastasis.\n* Any uncontrolled systemic disease, condition or comorbidity that, in the opinion of the Investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.\n* Persistent toxicities \\[Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 3\\] caused by previous anticancer therapy; alopecia and vitiligo are excluded toxicities.\n* Required the use of additional immunosuppression other than corticosteroids for the management of an adverse event or have experienced recurrence of an adverse event if re-challenged, or currently require maintenance doses of \\>10 mg prednisone or equivalent per day.\n* Receiving concurrent antiviral agent active against vaccinia virus (e.g., cidofovir, vaccinia immunoglobulin, imatinib, tecovirimat, or other agents with known anti-vaccinia activities).\n* Underwent major surgery within 4 weeks, or have insufficient recovery from surgical-related trauma or wound healing, prior to the planned first dose of treatment in either Arm.\n* Have received prior virus-based gene therapy or therapy with cytolytic virus of any type.\n* Vaccination against smallpox or monkeypox within 1 year of study therapy.\n* Any non-oncology vaccine therapy used for prevention of infectious diseases, such as seasonal (influenza) vaccinations, corona virus disease (COVID) vaccination or other vaccines, within 2 weeks of the planned first dose of study drug.\n* Clinically significant skin disease as assessed by the Investigator (e.g., severe eczema, psoriasis, or any unresolved skin injury or ulcer).\n* Known hypersensitivity to carboplatin, cisplatin, paclitaxel or nab-paclitaxel, docetaxel, or any of the constituents of Olvi-Vec (i.e., gentamicin).\n* Had severe hypersensitivity (CTCAE Grade ≥ 3) to ICI and\u002For any of its excipients previously.\n* Dementia or altered mental status that would prohibit informed consent, and\u002For psychiatric illness\u002Fsocial situations that might interfere or limit compliance with study requirements.","ALL","18 Years",{"count":334,"type":335},142,"ESTIMATED","INTERVENTIONAL",[338],"PHASE2","This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.",[341,342,343,344,345,346,347,348],"Advanced Non-squamous Non-small-cell Lung Cancer","Advanced Squamous Non-Small Cell Lung Carcinoma","Metastatic Non-squamous Non Small Cell Lung Cancer","Metastatic Squamous Non-Small Cell Lung Carcinoma","Non-small Cell Lung Cancer","Non-small Cell Lung Cancer Stage III","Non-small Cell Lung Cancer Stage IV","Non-small Cell Lung Cancer Recurrent",[39,350,351,352,353,354,355,356,357,358,359,360,361,362,363,364,365,366,367,368,369,370,371,372,373,374,375,376,377,378,379,380,381,382,383,384],"virotherapy","viral therapy","immunotherapy","immunochemotherapy","combination therapy","vaccinia virus","platinum-doublet chemotherapy","pembrolizumab","nivolumab","cemiplimab","atezolizumab","durvalumab","anti-PD-1","anti-PD-L1","carboplatin","cisplatin","docetaxel","neoplasms by site","neoplasms","carcinoma","Neoplasms by Histologic type","Antineoplastic Agents, Phytogenic","Antineoplastic Agents","Antimitotic Agents","Molecular Mechanisms of Pharmacological Action","Immune Checkpoint Inhibitors","NSCLC","NSCL cancer","chemoimmunotherapy","ICI","platinum resensitization","platinum resistant","chemoresistance","resensitize","olvimulogene nanivacirepvec","2026-06-02",{"date":387,"type":388},"2026-06-04","ACTUAL",{"date":390,"type":388},"2024-09-26",{"date":392,"type":335},"2029-07",{"name":5,"class":6},15]